News archive
November 2025
-
Media Release
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studies One-time dose of Itvisma… -
Media Release
Novartis announces plans to build flagship manufacturing hub in North Carolina
Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic… -
Story
Community Health Solutions: How We’re Meeting People Where They Are to Improve Community Health
Learn how community-driven partnerships are helping to break down barriers and support access to health care.
-
Story Education and Awareness
Five questions with Eden Wells, Chief Insights and Decision Science Officer at Novartis US
In this interview, Eden discusses the pivotal moments that shaped her career, her passion for advancing patient care and her vision for a future where timely and accessible healthcare is a reality for everyone.
-
Story
How This Former Army Officer Helps Deliver Cancer Treatments to Patients, Through Hurricanes and Beyond
Radioligand therapies harness the power of radioisotopes to target cancer with precision. For Matt Baca, delivering a dose in a three-to-five-day window is all in a day’s work.
-
Media Release
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of… -
Story Education and Awareness
Changing Lives: Inside the Novartis Corporate Teen Mentoring Program
At this award-winning two-day event, more than 150 high school students gathered to acquire professional skills that will empower them to lead successful futures.
-
Media Release
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolio C3…
October 2025
-
Media Release
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across… -
Media Release
Novartis showcases significant immunology advancements at ACR congress with new data in complex autoimmune diseases
Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell… -
Story Hope
Underserved but Not Out of Reach: 3 Ways to Bridge Care Gaps in Communities to Improve Advanced Prostate Cancer
Creating truly equal care for patients with advanced prostate cancer begins by learning from those often overlooked and help them feel seen, heard, and understood.
-
Media Release
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo…